Neoplasms

All Conditions

Rare Diseases

Sarcoma

Leiomyosarcoma

Sarcoma, Synovial

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

Synovial Sarcoma

pazopanib

GSK Clinical Trials

The purpose of this study is to evaluate the activity and tolerability of pazopanib in subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists and to characterize the pharmacokinetics of pazopanib in this subject population.

Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma

Progression free survival at week 12 is the number of participants who had a complete response (CR, all detectable tumor had disappeared) or a partial response (PR, a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum) or stable disease (SD, no change) 12 weeks from start of therapy, per response evaluation criteria in solid tumors (RECIST v1.0). Clinical progression is progression of disease without documented radiological evidence. Progressive disease (PD), a \>=20% increase in target lesions.

Overall survival is defined as the time from start of therapy until death. Participants who were still alive at the time of analysis were censored.

Progression free survival is defined as the interval between the start of treatment and the earliest date of disease progression or death due to any cause. Assessments of progression were made by the investigator.

Overall response is the number of participants who had a best outcome of a complete response (CR, all detectable tumor had disappeared) or a partial response (PR, a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum) per response evaluation criteria in solid tumors (RECIST v1.0) at some point during the study. Progressive disease (PD), a \>=20% increase in target lesions. Clinical progression is progression of disease without documented radiological evidence.

GlaxoSmithKline

Pazopanib 800 milligram (mg) (tablets) administered orally once a day

Pazopanib 800 mg

Includes all participants enrolled in the study

Age, Continuous

Sex: Female, Male

GSK Response Center

Complete Response

Partial Response

Stable Disease

Progressive Disease

Unknown

Missing

CR+PR+SD

Pazopanib 800 mg (tablets) administered orally once a day

Pazopanib 800 mg - Adipocytic Tumors

Pazopanib 800 mg - Leiomyosarcoma

Pazopanib 800 mg - Synovial Sarcoma

Pazopanib 800mg - Other Soft Tissue Sarcoma (STS)

Intent-to-Treat (ITT) Population: All eligible participants entered into the study and who had taken \>=1 dose of investigational product. Four participants were considered not evaluable for efficacy by the study coordinator for one of the following reasons: absence of target lesions, documented progression at trial entry, or ineligible histology.

Progression Free Survival at Week 12

ITT Population. Four participants were considered not evaluable for efficacy by the study coordinator for one of the following reasons: absence of target lesions, documented progression at trial entry, or ineligible histology.

Overall Survival

Intent-to-Treat (ITT) Population: all eligible participants who had started therapy. Four participants were considered not evaluable for efficacy by the study coordinator for one of the following reasons: absence of target lesions, documented progression at trial entry, or ineligible histology.

Spots Global Cancer Trial Database for Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial